Other
Erector Spinae Plane Block
2
Pipeline Programs↗
20
Active Trials↗
2
Companies Involved↗
Erector Spinae Plane Block is an early-stage landscape with 2 programs across 2 companies. The most active players are Fresenius Kabi Oncology Ltd., Eli Lilly. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
99
clinical trials
Completed57 · 58%
Unknown status17 · 17%
Recruiting8 · 8%
Not yet recruiting6 · 6%
Active, not recruiting4 · 4%
Withdrawn3 · 3%
Other4 · 4%
Clinical Trials
Trial Activity
99 trials
Dexmedetomidine in Sonographic Guided Erector Spinae Plane Block
Recruiting·—·Phase 2/3·NCT06899841·90 enrolled
Effect of Patient Position on Erector Spinae Plane Block in Thoracic Surgery
Not yet recruiting·—·N/A·NCT07387484·90 enrolled
Deep Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block in Pediatric Cardiac Patients Undergoing Primary Repair of Septal Defects Via Median Sternotomy
Not yet recruiting·—·Phase 3·NCT06873906·45 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)